ivermectin - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.40 [0.13, 1.23]< 10%3 studies (3/-)94.4 %some concernnot evaluable moderatecrucial-
deaths 0.43 [0.21, 0.87]< 10%6 studies (6/-)99.1 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.68 [0.29, 1.59]< 178%3 studies (3/-)81.5 %some concernnot evaluable moderateimportant-
clinical improvement 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.28 [0.61, 2.70]> 191%2 studies (2/-)74.5 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.89 [1.06, 3.38]> 10%1 study (1/-)98.4 %some concernnot evaluable moderateimportant-
death or ventilation 0.89 [0.30, 2.64]< 10%1 study (1/-)58.4 %some concernnot evaluable moderateimportant-
hospital discharge 1.14 [0.71, 1.84]> 10%2 studies (2/-)70.9 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.52 [0.19, 1.42]< 10%3 studies (3/-)90.0 %some concernnot evaluable moderateimportant-
viral clearance 0.92 [0.77, 1.09]> 10%1 study (1/-)17.3 %lownot evaluable highimportant-
viral clearance by day 7 0.91 [0.77, 1.08]> 10%2 studies (2/-)13.7 %some concernnot evaluable moderateimportant-
ICU admission 0.84 [0.39, 1.78]< 10%2 studies (2/-)67.9 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 2.14 [0.21, 21.56]< 10%2 studies (2/-)26.0 %some concernnot evaluable moderateimportant-
adverse events 1.97 [0.55, 7.04]< 136%3 studies (3/-)15.0 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.